BioCentury
ARTICLE | Clinical News

Lagova: Completed Phase III enrollment

July 20, 2015 7:00 AM UTC

Opko completed enrollment in a double-blind, placebo-controlled, international Phase III trial evaluating once-weekly hGH-CTP for 26 weeks in about 189 patients. The trial includes a 26-week open-labe...